<DOC>
	<DOCNO>NCT01751399</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question : - To evaluate much study drug ( LY2605541 ) blood participant vary degree liver impairment compare normal liver function - To assess safety LY2605541 side effect might associate</brief_summary>
	<brief_title>A Single Dose Study LY2605541 Participants With Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>All Participants ( include type 2 diabetes mellitus control diet ) Male participant agree use reliable method birth control study Female participant childbearing potential ( surgically sterilize menarche menopause ) must negative pregnancy test time enrollment must use reliable method birth control Women childbearing potential due surgical sterilization ( least 6 week surgical bilateral oophorectomy without hysterectomy least 6 week tubal ligation ) confirm medical history , menopause . Menopausal woman include woman either spontaneous amenorrhea least 12 month spontaneous amenorrhea 6 12 month folliclestimulating hormone ( FSH ) level great 40 milli international unit per milliliter ( mIU/mL ) Have body mass index ( BMI ) 18.5 40 kilogram per square meter ( kg/m^2 ) Have normal sit blood pressure heart rate compatible disease state Have venous access sufficient allow blood sample Have give write informed consent approve Lilly Ethical Review Board ( ERB ) govern site Participants Normal Hepatic Function Overtly healthy male female normal hepatic function Have clinical laboratory test result within normal reference range investigator site , result minor deviation consider clinically significant investigator Participants Hepatic Impairment Have stable liver impairment sign recent deterioration ( alcoholic , posthepatitis , biliary cirrhosis , cryptogenic ) classify ChildPugh class A , B , C consider investigator acceptable participation study All Participants ( include type 2 diabetes mellitus ) Are currently enrol , complete discontinue within last 30 day clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study Have acute infection fever infectious disease febrile illness within 3 day prior administration study medication Have know allergy significant hypersensitivity LY2605541 , excipients , related compound , history relevant allergic reaction origin Are person previously complete withdrawn study study investigate LY2605541 , previously receive investigational product Have Type 1 Diabetes Mellitus ( T1DM ) Type 2 Diabetes Mellitus ( T2DM ) receive antidiabetic medication Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus infection and/or positive human immunodeficiency virus ( HIV ) antibody Have donate blood 500 milliliter ( mL ) within last month Have liver transplant take immunosuppressant follow organ transplant Have show sign variceal bleed last 2 week prior screen Show evidence irritable bowel syndrome , chronic diarrhea , symptomatic digestive problem know history repeat chronic stool positive occult blood , consider investigator great risk acute chronic pancreatitis Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption duration study Are total parenteral nutrition Take anticoagulant therapeutic use , low dose acetylsalicyclic acid Are excessive consumer xanthines Participants Normal Hepatic Function Have medically significant history neurologic disease , cancer , cardiac , respiratory , metabolic , hepatic , renal , gastrointestinal ( except appendectomy cholecystectomy ) , dermatological , venereal , hematological disorder disease Have creatinine clearance ( CrCl ) less 80 milliliter per minute ( mL/min ) Show evidence significant active neuropsychiatric disease opinion investigator Show evidence hepatitis B and/or positive hepatitis B surface antigen Show evidence hepatitis C and/or positive hepatitis C antibody Participants Hepatic Impairment Show evidence significant active disease responsible associate mild , moderate , severe hepatic impairment Show evidence hepatorenal syndrome show creatinine clearance ( CrCl ) &lt; 50 milliliter per minute ( mL/min ) calculate use CockcroftGault equation Have show sign spontaneous bacterial peritonitis within 6 month prior enrollment study Have severe hyponatremia ( sodium &lt; 120 millimole per liter [ mmol/L ] ) Show sign hepatocellular carcinoma Have portal shunt Show , opinion investigator , evidence significant active neuropsychiatric disease grade 1 hepatic encephalopathy Have hemoglobin concentration &lt; 9.0 gram per deciliter ( g/dL ) Have platelet count &lt; 30 x 10^9 cell per liter ( cells/L ) , unless , consultation sponsor , consider acceptable participation study Have total serum bilirubin concentration &gt; 15 milligram per deciliter ( mg/dL ) ( &gt; 257 micromoles per liter ( Î¼mol/L ) ) Take medication know interfere hepatic metabolism ( example barbiturate , phenothiayines ) know alter major organ system Show sign acute cholestasis acute cholecystitis Have severe ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>